Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
Authors
Olivia Aranha
Washington University School of Medicine in St. Louis, St. Louis, MO
Olivia Aranha , Milind M. Javle , Minori Koshiji Rosales , Zishuo Ian Hu , Amir A. Faridi , Scott Paulson , Donald A. Richards , Howard S. Hochster , David Cosgrove , Nilofer Saba Azad , Ursa Brown-Glaberman , Vivian Jean M. Cline , Nathan M. Shumway , Mohamedtaki Abdulaziz Tejani , Sujatha Nallapareddy , Ilyas Sahin , Mitesh J. Borad , Lipika Goyal , Robin Kate Kelley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
Clinical Trial Registration Number
251040
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS587)
DOI
10.1200/JCO.2024.42.3_suppl.TPS587
Abstract #
TPS587
Poster Bd #
P16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.
First Author: Marilyn Fontaine
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
First Author: Jin Won Kim
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang